Single-Point Insulin Sensitivity Estimator (SPISE) as a Feasible Marker of Insulin Resistance in Adult Metabolic Syndrome: Evaluated in a Hospital Based Cross-Sectional Pilot Study at Tertiary Care Centre of Uttarakhand.
HOMA-IR
IRI
Insulin resistance
MetS
SPISE
TG/HDL-C ratio
Journal
Indian journal of clinical biochemistry : IJCB
ISSN: 0970-1915
Titre abrégé: Indian J Clin Biochem
Pays: India
ID NLM: 8708303
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
31
12
2020
accepted:
15
06
2021
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
ppublish
Résumé
Insulin resistance (IR) plays an important role as a major determinant of Metabolic syndrome (MetS). Various methods are available for measuring insulin resistance but they are laborious, time-consuming, and costly. Therefore various surrogate markers and indices have been devised to simplify and improve the determination of insulin resistance. Recently, a new index, single point insulin sensitivity estimator (SPISE) was proposed in the European population and was found comparable to the gold standard test (hyperinsulinemic euglycemic glucose clamp).This study was planned to evaluate whether SPISE could be a useful potential low-cost indicator for predicting MetS with IR patients in Indian population. Eighty-three participants from outpatient care of AIIMS Rishikesh were evaluated after informed consent. They were divided into Metabolic syndrome (n = 56) and Non Metabolic Syndrome(n = 27), using South Asian Modified National Cholesterol Education Program- ATP-III criteria for metabolic syndrome. SPISE index, HOMA-IR, Insulin Resistance Index, Triglycerides to high-density lipoproteins cholesterol ratio (TG/HDL-C) were calculated for all the subjects. Receiver operating characteristic (ROC) curve was plotted to assess discriminatory ability of SPISE, HOMA-IR, TG/HDL-C ratio, IRI and hs-CRP to differentiate between IR(Metabolic syndrome) and non-IR (Non-Metabolic syndrome) subjects. SPISE has greater area under curve with better sensitivity and specificity compared to HOMA-IR, IRI, TG/HDL-C ratio and hs CRP. So, SPISE has better predictive ability than HOMA-IR, IRI, TG/HDL-C ratio and hs CRP to discriminate IR from non-IR cases. SPISE could be a useful potential low-cost indicator with high sensitivity and specificity for predicting IR in MetS patients.
Identifiants
pubmed: 35873617
doi: 10.1007/s12291-021-00992-z
pii: 992
pmc: PMC9300811
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356-360Informations de copyright
© Association of Clinical Biochemists of India 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Diabetes Care. 2000 Mar;23(3):295-301
pubmed: 10868854
Am J Physiol. 1998 Apr;274(4):E592-9
pubmed: 9575818
World J Diabetes. 2010 May 15;1(2):36-47
pubmed: 21537426
Arch Cardiol Mex. 2006 Oct-Dec;76 Suppl 4:S173-88
pubmed: 17469345
Clin Chem. 2016 Sep;62(9):1211-9
pubmed: 27471037
J Lab Physicians. 2019 Jul-Sep;11(3):244-248
pubmed: 31579190
Toxicol Sci. 2018 Mar 1;162(1):36-42
pubmed: 29106690
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Ann Intern Med. 2003 Nov 18;139(10):802-9
pubmed: 14623617
Crit Rev Clin Lab Sci. 2015;52(4):180-90
pubmed: 26042993
Diabetes. 1988 Dec;37(12):1595-607
pubmed: 3056758
Diabetologia. 2010 Jan;53(1):144-52
pubmed: 19876614